Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

MS Drug May Be Effective in Treating Brain Cancer

Published research shows promise in using Sanofi’s multiple sclerosis drug Aubagio in addition to targeted cancer therapy to treat the aggressive brain cancer glioblastoma.

Read More »

Bristol-Myers’ Opdivo fails late-stage brain cancer trial

Bristol-Myers Squibb’s Opdivo failed to meet the main goal of a late-stage trial testing the immunotherapy in patients with an aggressive form of tumor that affects the brain or the spine.

Read More »

Can AI Detect Parkinson’s Disease from a Video? Tencent and Medopad Team up to Find Out

Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.

Read More »

Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain

Citing the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.

Read More »

Modified polio vaccine extends lives in U.S. brain cancer study

Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.

Read More »

FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

Genentech, a member of the Roche Group, announced that the U.S. FDA granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).

Read More »

The 7 Worst Clinical Disasters of 2016

It’s expected that a large number of clinical trials will result in failure. 2016 saw numerous trial failures, but analysts at The Motley Fool selected seven failures that are expected to have a direct impact on the forward outlooks of the companies involved.

Read More »

NovoCure’s cancer therapy effective in late-stage study

NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended trading. NovoCure’s therapy, Optune, which was evaluated in combination with Roche Holding AG’s cancer drug, reduced the risk of death by 39 percent in patients, […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom